Drugs / Revakinagene taroretcel
Revakinagene taroretcel
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT03319849 | Jan 2018 → Aug 2022 | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03316300 | Nov 2017 → Aug 2022 | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06971939 | Nov 2025 → Jan 2032 expected | macular telangiectasia type 2 | Neurotech Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Revakinagene taroretcel | “Revakinagene taroretcel (NT-501) is an encapsulated cell therapy producing ciliary neurotrophic factor that slowed retinal degeneration in patients with macular telangiectasia...” PMID 40693847 ↗ Jul 2025 |
| Known as | NT-501 | “Revakinagene taroretcel (NT-501) is an encapsulated cell therapy producing ciliary neurotrophic factor that slowed retinal degeneration in patients with macular telangiectasia...” PMID 40693847 ↗ Jul 20251“revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501)” NCT06971939 ↗ |
| Known as | revakinagene taroretcel-lwey | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06971939 ↗ |
| Modality | Cell therapy | “encapsulated cell therapy” PMID 40693847 ↗ Jul 2025 |
| Route | Intravitreal | “into the vitreous cavity” NCT03316300 ↗ |